US2018235935A1PendingUtilityA1

Treatment of Cancer with Enzalutamide and a CYP3A4 Inhibitor

Assignee: MEDIVATION PROSTATE THERAPEUTICS LLCPriority: Aug 12, 2015Filed: Aug 11, 2016Published: Aug 23, 2018

Est. expiryAug 12, 2035(~9 yrs left)· nominal 20-yr term from priority

Inventors:Jacqueline A. Gibbons Joyce Mordenti Michiel De Vries Walter Krauwinkel

A61K 2300/00A61K 31/4166A61K 31/55A61P 35/00A61K 31/515A61K 31/496A61K 31/435A61K 31/438A61K 45/06

PatentIndex Score

Cited by

References

Claims

Abstract

This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer in the treatment of cancer.

Claims

exact text as granted — not AI-modified

1 . A method of treating cancer, comprising co-administration to a patient in need thereof a therapeutically effective dose of enzalutamide and a CYP3A4 inducer, wherein the therapeutically effective dose of enzalutamide is 200-300 mg per day. 
     
     
         2 . The method of  claim 1 , wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, and ovarian cancer. 
     
     
         3 . The method of  claim 1 , wherein the therapeutically effective dose of enzalutamide is 240 mg per day. 
     
     
         4 . A method of treating metastatic castration-resistant prostate cancer, comprising co-administration to a patient in need thereof (i) 240 mg/day of enzalutamide and (ii) a CYP3A4 inducer. 
     
     
         5 . The method of  claim 1 , wherein the CYP3A4 inducer is selected from the group consisting of carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and rifapentine. 
     
     
         6 . The method of  claim 4 , wherein the CYP3A4 inducer is selected from the group consisting of carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and rifapentine.

Join the waitlist — get patent alerts

Track US2018235935A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.